Wambolt & Associates LLC Reduces Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Wambolt & Associates LLC lowered its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 33.1% in the first quarter, HoldingsChannel reports. The institutional investor owned 1,077 shares of the medical equipment provider’s stock after selling 533 shares during the period. Wambolt & Associates LLC’s holdings in Intuitive Surgical were worth $425,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Baystate Wealth Management LLC grew its stake in Intuitive Surgical by 150.0% during the 4th quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 45 shares during the last quarter. MCF Advisors LLC lifted its stake in Intuitive Surgical by 108.1% during the 4th quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 40 shares during the period. Headinvest LLC purchased a new stake in shares of Intuitive Surgical in the 3rd quarter valued at $28,000. Able Wealth Management LLC acquired a new stake in shares of Intuitive Surgical in the fourth quarter worth $28,000. Finally, Atticus Wealth Management LLC raised its holdings in shares of Intuitive Surgical by 85.4% during the fourth quarter. Atticus Wealth Management LLC now owns 89 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 41 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Stock Performance

Shares of NASDAQ:ISRG traded up $8.95 during midday trading on Friday, hitting $443.76. The company’s stock had a trading volume of 1,114,523 shares, compared to its average volume of 1,317,312. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $448.10. The company has a market cap of $157.40 billion, a P/E ratio of 80.10, a price-to-earnings-growth ratio of 5.62 and a beta of 1.39. The business’s 50 day simple moving average is $410.21 and its 200 day simple moving average is $386.57.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.10. The business had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The business’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.00 EPS. On average, sell-side analysts predict that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Citigroup upped their price target on shares of Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. The Goldman Sachs Group initiated coverage on shares of Intuitive Surgical in a research note on Thursday, May 30th. They set a “buy” rating and a $500.00 price objective on the stock. Robert W. Baird decreased their target price on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a research note on Friday, April 19th. BTIG Research raised their price target on shares of Intuitive Surgical from $412.00 to $421.00 and gave the company a “buy” rating in a research report on Friday, April 19th. Finally, Jefferies Financial Group upped their price objective on shares of Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a research report on Friday, April 19th. Six research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, Intuitive Surgical currently has an average rating of “Moderate Buy” and a consensus price target of $404.79.

Insiders Place Their Bets

In other news, SVP Mark Brosius sold 175 shares of Intuitive Surgical stock in a transaction on Monday, May 13th. The stock was sold at an average price of $389.16, for a total transaction of $68,103.00. Following the transaction, the senior vice president now owns 883 shares in the company, valued at approximately $343,628.28. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Intuitive Surgical news, EVP Myriam Curet sold 5,318 shares of Intuitive Surgical stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $370.66, for a total value of $1,971,169.88. Following the sale, the executive vice president now owns 298 shares in the company, valued at $110,456.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Mark Brosius sold 175 shares of the stock in a transaction on Monday, May 13th. The stock was sold at an average price of $389.16, for a total value of $68,103.00. Following the transaction, the senior vice president now owns 883 shares of the company’s stock, valued at $343,628.28. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 17,956 shares of company stock valued at $6,927,011. Insiders own 0.80% of the company’s stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.